News from Wednesday, September 10, 2025
Articles
Biomarker Insights Differentiate JAK1 vs IL-13 Therapy in AD
(9/10, Maggie L. Shaw, The American Journal of Managed Care) reports “...Janus kinase 1 (JAK1) inhibitors showed potential superior efficacy vs anti–IL-13 antibodies among 75 patients receiving treatment for moderate to severe atopic dermatitis (AD), with authors noting their increased antipruritic effects as soon as 3 months.” Full
Patient Experience Dossiers: Connecting Decision Makers With Patient-Centered Evidence
(9/9, Elisabeth M. Oehrlein, Health Affairs Forefront) comments “...As the PE Dossier Template continues to evolve, it holds significant promise for reshaping how patient perspectives are integrated into health care decisions. By providing a structured, centralized approach to capturing and sharing patient experiences, the template offers a scalable solution to bridge the gaps that currently fragment patient-centered evidence...The template’s adoption by patient groups and engagement from biopharmaceutical companies, regulators, value/HTA, and payers signal a critical step toward more informed, patient-centered conversations across the healthcare ecosystem.” Full
Germany: CSL’s Andembry HTA Submission Offers Critical Indirect Comparison Lessons
(9/9, Francesca Bruce, Pink Sheet) reports “...Health technology assessment authorities in Germany have concluded that CSL Behring’s Andembry offers significant additional benefits for hereditary angioedema patients, which could strengthen the company’s position during pricing negotiations.” Subscription Required
Press Releases
Fertility Clinics must End Unproven Treatments That Don't Help Couples Have Babies
(9/10, NICE Press Release) “...The updated recommendations specifically advise against several popular fertility ‘add-ons’ that are being offered to those having private and NHS fertility treatment in the UK, despite no clear evidence that they work. The draft guideline also recommends offering fertility preservation to a wider range of people who are undergoing a medical treatment that might affect their future chances of having a baby. Currently this is mostly offered to patients with cancer.” Full
Journals
Comparative Short-Term Efficacy of Janus Kinase 1 Inhibitors and Anti-Interleukin-13 Antibodies in Atopic Dermatitis: A Retrospective Cohort Analysis Based on Real-World Data
Emi Sato, et al.
August 10, 2025, Frontiers in Immunology
Comparative Safety of JAK Inhibitors vs TNF Antagonists in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis
Virginia Solitano, et al.
September 2, 2025, JAMA Network Open
Choosing the Best First-line Therapy for Extensive-Stage Small-Cell Lung Cancer: anti-PD-1 or anti-PD-L1 Inhibitors?
Shengyu Zhu, et al.
September 5, 2025, Medicine (Baltimore)
Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial
Alexander B.C.D. Ng, MBBS; Aqua Asif, MBChB; Ridhi Agarwal, PhD, et al.
September 10, 2025, JAMA
Cost Effectiveness of the 15 Drugs Selected for IPAY 2027 CMS Drug Price Negotiation
Feng Xie, PhD, et al.
September 10, 2025, Value in Health
Composite Endpoints in Health Technology Assessment: Part 1 – An Illustration of Best Modeling Practice
Andrew Briggs, et al.
September 10, 2025, Journal of Comparative Effectiveness Research
Journal of Comparative Effectiveness Research
Composite Endpoints in Health Technology Assessment: Part 2 – Expanding the Evidence Base with a Framework for Best Modeling Practice
Andrew Briggs, et al.
September 10, 2025, Journal of Comparative Effectiveness Research